Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 17,726 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Population Clear all
Completed No phase listed Observational

Grade Book Game Evaluation Among 6th Grade Students

NCT03039894
View directory record Official record
Conditions
Adolescent Behaviors
Interventions
Gradebook Game
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 17 Years
Enrollment
100 participants
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement

NCT00681356
View directory record Official record
Conditions
Total Knee Arthroplasty (Replacement)
Interventions
4975, 15 and 5 mg, Placebo Comparator, 4975 - 5 mg
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 20 more
Source: ClinicalTrials.gov public record
Updated May 4, 2009 · Synced Oct 23, 2026, 5:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Microbiome Dysfunction in Surgical Intensive Care Unit Survivors

NCT05357170
View directory record Official record
Conditions
Sepsis, Trauma Injury
Interventions
Human feces collection
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 110 Years
Enrollment
468 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 23, 2026, 5:05 AM EDT
Terminated Not applicable Interventional Results available

Transcranial Direct Current Stimulation, Improve Functional Motor Recovery, Affected Arm

NCT01201629
View directory record Official record
Conditions
Brain Infarction, Brain Ischemia
Interventions
t DC stimulation, tDCStimulation
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
19 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Not applicable Interventional

Role of Home-Based Transcutaneous Electrical Acustimulation for Treatment of Pain in Subjects With Chronic Pancreatitis

NCT06721572
View directory record Official record
Conditions
Chronic Pancreatitis, Pancreatitis
Interventions
TEA
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 23, 2026, 5:05 AM EDT
Terminated Not applicable Interventional

Exercise Preconditioning with Cancer Surgeries

NCT04923672
View directory record Official record
Conditions
Colorectal Cancer, Hepatobiliary Cancer, Gynecologic Cancer
Interventions
Moderate continuous exercise, High intensity interval exercise
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Results available

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

NCT04456673
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 85 Years
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
92
States / cities
Cullman, Alabama • Jasper, Alabama • Scottsboro, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

NCT05802173
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
North Little Rock, Arkansas • Rolling Meadows, Illinois • Plainfield, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients

NCT01197794
View directory record Official record
Conditions
Asthma Patients
Interventions
AZD1981, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Fullerton, California • Los Angeles, California • Mission Viejo, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Results available

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

NCT01813422
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
59
States / cities
Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects

NCT02257151
View directory record Official record
Conditions
Healthy Adult
Interventions
BMS-986142, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

NCT01756898
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
5 mg ASB17061, Placebo, 10 mg ASB17061, 20 mg ASB17061
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 65 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 23, 2026, 5:05 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT04974398
View directory record Official record
Conditions
Nasopharyngeal Carcinoma
Interventions
Penpulimab, placebo
Drug
Lead sponsor
Akeso
Industry
Eligibility
12 Years to 75 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Duarte, California • Atlanta, Georgia • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 23, 2026, 5:05 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice

NCT07528963
View directory record Official record
Conditions
Cancer Survivorship, Primary Care
Interventions
KanSurvive telementoring and education, Practice facilitation for quality improvement, Obesity management toolkit, Survivorship Care Manual, Virtual scribe services
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

NCT01954251
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
829 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Phoenix, Arizona • Carnegie, Pennsylvania • Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Not applicable Interventional Results available

The Effect of Reducing Posttraumatic Stress Disorder Symptoms on Cardiovascular Risk

NCT02736929
View directory record Official record
Conditions
PTSD
Interventions
Cognitive Processing Therapy - Cognitive
Behavioral
Lead sponsor
Duke University
Other
Eligibility
40 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 3 Interventional

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

NCT00064402
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
Interventions
arformoterol tartrate inhalation solution, Salmeterol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
65
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia

NCT03934099
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
LC350189 formulated capsule, Placebo
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
34
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Phase 2 Interventional

Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis

NCT00539929
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
E6201 0.005%, E6201 0.01%, E6201 0.03%, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Hot Springs, Arkansas • San Diego, California • Boise, Idaho + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Social Media Support and Financial Incentives on PrEP Adherence

NCT03078153
View directory record Official record
Conditions
Pre-Exposure Prophylaxis
Interventions
Financial Incentive, Social Media Group
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 24 Years · Male only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 23, 2026, 5:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sedentary Behavior Interrupted Randomized Controlled Trial (P2)

NCT03473145
View directory record Official record
Conditions
Sedentary Lifestyle
Interventions
Health Coaching, activPAL inclinometer, Tools to Prompt Standing or Prompt Sit-to-Stand Transitions.
Behavioral · Device · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
55 Years and older · Female only
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 23, 2026, 5:05 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult Subjects

NCT04104399
View directory record Official record
Conditions
Migraine
Interventions
XC101-D13H, Placebo
Drug
Lead sponsor
Xoc Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 23, 2026, 5:05 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Role of Mobile Apps in Promoting Cardiovascular Health and Motivation to Exercise During Pregnancy

NCT07166822
View directory record Official record
Conditions
Cardiovascular (CV) Risk, Exercise
Interventions
Experimental group using BumptUp mobile exercise app
Behavioral
Lead sponsor
Old Dominion University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 23, 2026, 5:05 AM EDT
Recruiting Not applicable Interventional

Matching Treatments to Cognitive Deficits in Offenders With Substance Use Disorders

NCT06981351
View directory record Official record
Conditions
Antisocial Behavior
Interventions
Attention to Context (ATC) training, Affective Cognitive Control (ACC) training
Behavioral
Lead sponsor
The Mind Research Network
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 23, 2026, 5:05 AM EDT